Genomic Vision Hosts Inaugural R&D Day with Its Long-Standing Partner Quest Diagnostics
April 20 2017 - 4:11AM
Business Wire
- The Company will present its main
molecular diagnostic programs with its industrial and academic
partners
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a biotech
company specialized in the development of diagnostic tests for the
early detection of cancers and genetic diseases, will host a first
R&D Day on May 10th, 2017, in the Imagine Institute (Necker
Hospital, Paris).
This event dedicated to the investors, the analysts and the
press will allow them to deepen their knowledge on the main GENOMIC
VISION’s R&D programs through presentations led with its
historical industrial partner QUEST DIAGNOSTICS and several
academic teams.
The program of the R&D Day includes the following
presentations:
- 9h30: Inaugural speechAaron
Bensimon – CEO of GENOMIC VISION
- 9h45: Pediatric Spinal Muscular
Atrophy – SMA program presentationPr Arnold Munnich, Head
of Genetic Service at the Necker Hospital -
Enfants-Malades
- 10h15: “Quest Diagnostics genetic
testing frontiers and DNA combing program”Jay Wohlgemuth,
Senior VP, CMO of Quest DiagnosticsEdward Ginns, M.D, Ph.D, Medical
director – Neurology - Quest Diagnostics
- 10h45: Myopathy:
Facioscapulohumeral Muscular Dystrophy – “(R)Evolution of
Diagnostic approaches in FSHD1 towards multi-allelic determination
by molecular combing”Pr Nicolas Levy, Head of Medical Genetics
department at the Children's Hospital La Timone (Marseille,
France)
- 11h15: Cervical Cancer Diagnostic
and Prognostic– Presentation of the HPV program conducted in Czech
RepublicDr. Vladimír Dvořák, Brno Centre for Outpatient
Gynecology and Primary Care), principal investigator of the HPV
pilot studyDr Petr Janda, CEO of PCS (Prague Clinical
Services)
- 11h45: Round-table hosted by Fabrice
Papillon:“Which strategies for the screening of the genetic
diseases in the future? What pathologies in sights? "
Aaron Bensimon, CEO of Genomic Vision, declared: “We are
very honored to invite our investors, financial analysts and the
press to this event to present in detail all of our clinical
diagnostic programs notably with the presence of Quest Diagnostics,
our historic industrial partner. I hope that this R&D Day will
serve to highlight in detail Genomic Vision’s technological and
commercial strategy. Finally, these scientific and medical
presentations will underline the acceleration of our innovations
and our partnerships. This acceleration is an important measure of
short, medium and long-term value creation”.
In addition, GENOMIC VISION will organize a second R&D Day
in next autumn during which the management team will present the
advantages of our technology in the field of Life Sciences
Research, particularly in safety control in the gene editing and
DNA replication.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotech company specialized in the
development of diagnostic solutions for the early detection of
cancers and serious genetic diseases and tools for life sciences
research. Through the DNA Molecular Combing, a strong proprietary
technology allowing to identify genetic abnormalities, GENOMIC
VISION stimulates the R&D productivity of the pharmaceutical
companies, the leaders of the diagnostic industry and the research
labs.The Company develops a robust portfolio of diagnostic tests
(breast, ovarian and colorectal cancers, myopathies) and analysis
tools (DNA replication, biomarkers discovery, gene editing quality
control). Based near Paris, in Bagneux, the Company has
approximately 60 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV - ISIN: FR0011799907).For further information,
please visit www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENTThis press release contains
implicitly or explicitly certain forward-looking statements
concerning Genomic Vision and its business.Such forward-looking
statements are based on assumptions that Genomic Vision considers
to be reasonable. However, there can be no assurance that such
forward-looking statements will be verified, which statements are
subject to numerous risks, including the risks set forth in the
“Risk Factors” section in its Document de Reference filed with the
French Autorité des Marchés Financiers (AMF) on April 28, 2017,
under number R.17-009, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170420005569/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel. : +33 1 49 08 07
50investisseurs@genomicvision.comorMilestonesPress
RelationsBruno ArabianTel. : +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel HuynhTel. : +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2024 to May 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From May 2023 to May 2024